In preclinical models of NB, the combination of adoptively transferred Vδ2+ T cells (expanded in vitro with ZOL and IL-2) with anti-GD2 antibody ch14.18/CHO and with ZOL significantly suppressed tumor growth as compared to controls. The gene discussed is IL2; the disease is neoplasm.